{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:15:06Z","timestamp":1783509306643,"version":"3.55.0"},"reference-count":29,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC200132"],"award-info":[{"award-number":["20252BAC200132"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Province Key Laboratory of Immunology and Inflammation","award":["2024SSY06251"],"award-info":[{"award-number":["2024SSY06251"]}]},{"name":"Jiangxi Provincial Health Technology Project","award":["2026Y0002"],"award-info":[{"award-number":["2026Y0002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371773"],"award-info":[{"award-number":["82371773"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Provincial Health Technology Key Project","award":["2024ZD003"],"award-info":[{"award-number":["2024ZD003"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to elucidate the potential pharmacological mechanisms by which colchicine confers clinical benefits in patients with atherosclerotic cardiovascular disease, focusing on its effects on cholesterol efflux.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted in multiple cellular models. First, cell viability was assessed and the optimal dosage of colchicine was screened via the Cell Counting Kit-8 assay. Subsequently, Oil Red O staining, commercial kit detection and Boron dipyrromethene (BODIPY) -cholesterol labelling were employed to analyse intracellular lipid accumulation, foam cell formation and cholesterol efflux rate in macrophages, respectively. Furthermore, molecular docking and transcriptome sequencing were performed to explore the potential therapeutic targets and underlying mechanisms of colchicine, followed by a series of cellular experiments (quantitative reverse transcription-PCR, ATP-binding cassette transporter A1 (ABCA1) degradation analysis, plasmid construction and transfection, co-immunoprecipitation, immunoblotting) for comprehensive validation of the identified potential mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the present study, we demonstrate that colchicine markedly promotes cholesterol efflux, a key process that reverses macrophage foam cell formation and consequently contributes to its cardioprotective effects. We identified modulation of the ubiquitination of ABCA1 as the pivotal mechanism by which colchicine enhances cholesterol efflux. Our findings reveal for the first time that denticleless E3 ubiquitin protein ligase homologue (DTL) functions as a crucial E3 ligase in this regulatory pathway. Mechanistically, colchicine suppresses DTL expression and disrupts its interaction with ABCA1, leading to increased ABCA1 protein stability, enhanced ABCA1-mediated cholesterol efflux and a subsequent reduction in foam cell formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Colchicine shows great promise for drug repurposing as a novel therapeutic agent. Its strong capacity to reverse foam cell formation highlights its potential to extend clinical use beyond gout management to cardiovascular secondary prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006553","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:20:21Z","timestamp":1783506021000},"page":"e006553","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Colchicine enhances macrophage cholesterol efflux by targeting DTL-mediated ubiquitination and degradation of ABCA1"],"prefix":"10.1136","volume":"12","author":[{"given":"Lingfei","family":"Tong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-4675","authenticated-orcid":false,"given":"Lihua","family":"Duan","sequence":"additional","affiliation":[{"name":"Jiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial People\u2019s Hospital, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5521-9069","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070803201383000_12.3.e006553.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab221"},{"key":"2026070803201383000_12.3.e006553.2","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/eurheartj\/ehab276","article-title":"Coronary artery disease: \u201cgout\u201d in the artery?","volume":"42","author":"Strandberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2026070803201383000_12.3.e006553.3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1001\/jama.2024.12935","article-title":"Diagnosis, risk stratification, and treatment of pericarditis: a review","volume":"332","author":"Cremer","year":"2024","journal-title":"JAMA"},{"key":"2026070803201383000_12.3.e006553.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.055"},{"key":"2026070803201383000_12.3.e006553.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388"},{"key":"2026070803201383000_12.3.e006553.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372"},{"key":"2026070803201383000_12.3.e006553.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2024.01.004","article-title":"The impact of colchicine on patients with acute and chronic coronary artery disease","volume":"125","author":"Madanchi","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026070803201383000_12.3.e006553.8","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/eurheartj\/ehad453","article-title":"Colchicine for cardiovascular prevention: the dawn of a new era has finally come","volume":"44","author":"Bonaventura","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070803201383000_12.3.e006553.9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"2026070803201383000_12.3.e006553.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.898690","article-title":"Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation","volume":"13","author":"Meyer-Lindemann","year":"2022","journal-title":"Front Immunol"},{"key":"2026070803201383000_12.3.e006553.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.12.027"},{"key":"2026070803201383000_12.3.e006553.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050560"},{"key":"2026070803201383000_12.3.e006553.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.09.148"},{"key":"2026070803201383000_12.3.e006553.14","doi-asserted-by":"publisher","DOI":"10.1038\/nature16959"},{"key":"2026070803201383000_12.3.e006553.15","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.476","article-title":"Cholesterol metabolism: physiological regulation and diseases","volume":"5","author":"Guo","year":"2024","journal-title":"MedComm"},{"key":"2026070803201383000_12.3.e006553.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2009.94"},{"key":"2026070803201383000_12.3.e006553.17","doi-asserted-by":"crossref","first-page":"17280","DOI":"10.3390\/ijms242417280","article-title":"MP allosterically activates AMPK to enhance ABCA1 stability by retarding the calpain-mediated degradation pathway","volume":"24","author":"Li","year":"2023","journal-title":"IJMS"},{"key":"2026070803201383000_12.3.e006553.18","doi-asserted-by":"crossref","first-page":"101689","DOI":"10.1016\/j.beem.2022.101689","article-title":"The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I","volume":"37","author":"Thomas","year":"2023","journal-title":"Best Practice & Research Clinical Endocrinology & Metabolism"},{"key":"2026070803201383000_12.3.e006553.19","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/S0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs high-density lipoprotein intervention trial","volume":"86","author":"Boden","year":"2000","journal-title":"Am J Cardiol"},{"key":"2026070803201383000_12.3.e006553.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"2026070803201383000_12.3.e006553.21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jare.2021.01.009","article-title":"Naringenin ameliorates homocysteine induced endothelial damage via the AMPK\u03b1\/Sirt1 pathway","volume":"34","author":"Li","year":"2021","journal-title":"J Adv Res"},{"key":"2026070803201383000_12.3.e006553.22","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01380-1"},{"key":"2026070803201383000_12.3.e006553.23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060815-014922"},{"key":"2026070803201383000_12.3.e006553.24","doi-asserted-by":"crossref","first-page":"106814","DOI":"10.1016\/j.phrs.2023.106814","article-title":"The burden of hypercholesterolemia and ischemic heart disease in an ageing world","volume":"193","author":"Pirillo","year":"2023","journal-title":"Pharmacol Res"},{"key":"2026070803201383000_12.3.e006553.25","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001303"},{"key":"2026070803201383000_12.3.e006553.26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40292-016-0155-2","article-title":"Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk","volume":"23","author":"Agabiti Rosei","year":"2016","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2026070803201383000_12.3.e006553.27","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M054742"},{"key":"2026070803201383000_12.3.e006553.28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.675579"},{"key":"2026070803201383000_12.3.e006553.29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbalip.2017.12.011","article-title":"The E3 ubiquitin ligase, HECTD1, is involved in ABCA1-mediated cholesterol export from macrophages","volume":"1863","author":"Aleidi","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:20:23Z","timestamp":1783506023000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2025-006553"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006553","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}